Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer

Prostate

Volumn 62, Issue 3, 2005, Pages 267-274

  Härkönen, Päivi ^a   Kyllönen, Atte P ^a   Nordling, Stig ^b   Vihko, Pirkko ^a  

^a UNIVERSITY OF OULU   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Allelic loss; Chromosome arm 16q; Prostate carcinoma

Indexed keywords

DNA;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENESIS; CHROMOSOME 16Q; CLINICAL ARTICLE; CONTROLLED STUDY; GENE LOCATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA;

CHROMOSOMES, HUMAN, PAIR 16; DINUCLEOTIDE REPEATS; DISEASE PROGRESSION; DNA, NEOPLASM; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 12344280985     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20147     Document Type: Article

References (30)

1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
2. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-347.
3. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-806.
4. Elo JP, Härkönen P, Kyllönen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko P. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997;57:3356-3359.
5. Elo JP, Härkönen P, Kyllönen AP, Lukkarinen O, Vihko P. Three independently deleted regions at chromosome arm 16q in human prostate cancer: Allelic loss at 16q24.1-q24.2 is associated with aggressive behavior of the disease, recurrent growth, poor differentiation of the tumour, and poor prognosis for the patient. Br J Cancer 1999;79:156-160.
6. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 1996;17:225-233.
7. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions. Cancer Res 1997;57:1058-1062.
8. Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 2003;63:4781-4785.
9. Mostofi FK. Histological typing of prostate tumors. Geneva: World Health Organization; 1980.
10. Wright DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: A guide to methods and applications. California: Academic Press, Inc.; 1990. pp. 153-158.
11. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 1996;380:152-154.
12. Durocher F, Morissette J, Labrie Y, Labrie F, Simard J. Mapping of the HSD17B2 gene encoding type II 17β-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. Genomics 1995;25:724-726.
13. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996;56:3331-3337.
14. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated prostate cancer metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56:3091-3102.
15. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schroder FH, van der Kwast TH, Bosman FT, van Dekken H. Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 1997;77:437-448.
16. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-148.
17. Härkönen P, Törn S, Kurkela R, Porvari K, Pulkka A, Lindfors A, Isomaa V, Vihko P. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab 2003;88:705-712.
18. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci 1990;87:8751-8755.
19. Lee SW. H-cadherin: A novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med 1996;2:776-782.
20. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 1998;103:96-101.
21. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gadzar AF. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001;61:4556-4560.
22. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnel J, Frenkel EP, Gazdar AF. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-519.
23. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ, Gazdar AF. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 2002;62:3382-3386.
24. Kremmidiotis G, Baker E, Crawford J, Eyre HJ, Nahmias J, Callen DF. Localization of human cadherin genes to chromosome regions exhibiting cancer-related loss of heterozygosity. Genomics 1998;49:467-471.
25. Whitmore SA, Settasatian C, Crawford J, Lower KM, McCallum B, Seshadri R, Cornelisse CJ, Moerland EW, Cleton-Jansen AM, Tipping AJ, Mathew CG, Savnio M, Savoia A, Verlander P, Auerbach AD, Van Berkel C, Pronk JC, Doggett NA, Callen DF. Characterization and screening for mutations of the growth arrest-specific 11 (GAS11) and C16orf3 genes at 16q24.3 in breast cancer. Genomics 1998;52:325-331.
26. Pullman WE, Bodmer WF. Cloning and characterization of a gene that regulates cell adhesion. Nature 1992;356:529-532.
27. Grana X, Claudio PP, De Luca A, Sang N, Giordano A. PISSLRE: A human novel CDC2-related protein kinase. Oncogene 1994;9:2097-2103.
28. Brambilla R, Draetta G. Molecular cloning of PISSLRE: A novel putative member of the cdk family of protein serine/threonine kinases. Oncogene 1994;9:3037-3041.
29. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S. Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2: A microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J Biol Chem 1993;268:12964-12969.
30. Miettinen MM, Mustonen MV, Poutanen MH, Isomaa W, Vihko RK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 1996;314:839-845.